CIK 0001434647 · Non-accelerated filer<br>Smaller reporting company
ZEVRA THERAPEUTICS, INC.
Sign in to watch- Ticker
- ZVRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205894398
- Phone
- (888) 958-1253
- Business address
- 101 FEDERAL STREET, BOSTON, MA, 02110
- Former names
- KEMPHARM, INC, KEMPHARM INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $224,948
- in 1 filing, $225K under 10b5-1 plans
Net −$224,948. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-24 | Bode John B Director | Option exercise | +39,200 | $4.89 | $192K | 123,400 |
| 2026-03-24 | Bode John B Director | Option exercise · Stock Option (right to buy) | −39,200 | 19,600 | ||
| 2026-03-24 | Bode John B Director | Option exercise · Stock Option (right to buy) | −39,200 | 0 | ||
| 2026-03-18 | Renz Justin A CFO | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2026-02-09 | McFarlane Neil F. President and CEO | Sale 10b5-1 | −14,625 | $8.56 | $125K | 387,225 |
| 2026-02-07 | McFarlane Neil F. President and CEO | Option exercise 10b5-1 | +37,500 | 401,850 | ||
| 2026-02-07 | McFarlane Neil F. President and CEO | Option exercise · Restricted Stock Unit 10b5-1 | −37,500 | 75,000 | ||
| 2026-02-03 | Schafer Joshua CCO | Sale 10b5-1 | −10,500 | $9.19 | $97K | 62,278 |
| 2026-02-03 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Sale 10b5-1 | −3,000 | $9.18 | $28K | 29,590 |
| 2026-02-02 | McFarlane Neil F. President and CEO | Sale 10b5-1 | −91,000 | $9.38 | $853K | 364,350 |
| 2026-01-31 | Schafer Joshua CCO | Option exercise 10b5-1 | +35,334 | 72,778 | ||
| 2026-01-31 | Schafer Joshua CCO | Option exercise · Restricted Stock Unit 10b5-1 | −35,334 | 35,333 | ||
| 2026-01-31 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Option exercise 10b5-1 | +11,666 | 32,590 | ||
| 2026-01-31 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Option exercise · Restricted Stock Unit 10b5-1 | −11,666 | 11,668 | ||
| 2026-01-31 | McFarlane Neil F. President and CEO | Option exercise 10b5-1 | +233,334 | 455,350 | ||
| 2026-01-31 | McFarlane Neil F. President and CEO | Option exercise · Restricted Stock Unit 10b5-1 | −233,334 | 233,333 | ||
| 2026-01-30 | Schafer Joshua CCO | Option exercise 10b5-1 | +11,333 | 40,819 | ||
| 2026-01-30 | Schafer Joshua CCO | Sale 10b5-1 | −3,375 | $8.83 | $30K | 37,444 |
| 2026-01-30 | Schafer Joshua CCO | Option exercise · Restricted Stock Unit 10b5-1 | −11,333 | 22,667 | ||
| 2026-01-30 | Quartel Adrian W Chief Medical Officer | Option exercise 10b5-1 | +11,333 | 14,256 |
Page 2 of 9 · 166 trades